The Independent reported that the British drug maker AstraZeneca has agreed a $1.26bn (£781m) deal to buy San Diego firm Ardea Biosciences.
AstraZeneca which is the UK 2nd biggest drug developer is currently looking for new products, acquiring Ardea also means that Astra Zeneca gains a drug called Lesinurad,
Ardea, California-based biotechnology company focused on the development of small-molecule therapeutics. Ardea's top drug Lesinurad is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout. This disease is expected to affect almost 17 million people by 2019.
David Brennan, AstraZeneca's chief executive, said: This attractive Phase III programme is an excellent opportunity to leverage AstraZeneca's global specialty and primary care sales and marketing capabilities.....The Ardea team has done a great job developing Lesinurad along with a promising next-generation gout programme. These compounds have real potential to benefit patients.”
Click here to see our clinical roles in the UK and Europe
Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates
